Plantibodies | Technology Platform, Therapeutic Pipeline & Pharma Partnerships

Plantibodies

Pioneering a New Generation of GI-Restricted Oral Biologics

Proprietary technology. Differentiated therapeutics. Industrial manufacturing. Pharmaceutical partnerships.

Executive Summary

Plantibodies is a Paris-based biotechnology company developing a proprietary plant-cell platform for the production and oral delivery of biologic therapeutics.

The company is pioneering an approach to GI-restricted oral biologics: therapeutic proteins designed to act locally within the gastrointestinal tract, with limited systemic exposure.

Plantibodies addresses an important opportunity in pharmaceutical innovation. While biologic medicines have transformed the treatment of many diseases, their administration remains predominantly systemic. For therapeutic applications where the gastrointestinal tract is the intended site of action, localized oral delivery offers the potential to create differentiated medicines with targeted pharmacological activity and a convenient administration route.

Plantibodies combines recombinant biologic expression in plant cells, bioencapsulation technology and therapeutic product development within an integrated platform.

The company operates through two complementary business models:

  • Proprietary therapeutic development: Advancing an internal pipeline of GI-restricted biologic medicines.
  • Pharmaceutical partnerships: Applying its proprietary technology to selected biologic assets from pharmaceutical and biotechnology partners.

Plantibodies is already working with multiple pharmaceutical companies on confidential applications involving their proprietary pipelines.

The company has also established large-scale GMP manufacturing capabilities validated in collaboration with third-party industrial partners, providing an industrial foundation for pharmaceutical development.

Specific therapeutic targets, pipeline candidates and collaboration details are not publicly disclosed in order to protect intellectual property and partner confidentiality.

Plantibodies is positioned at the intersection of biologic innovation, localized gastrointestinal therapy and scalable plant-based biomanufacturing.


1. The Unmet Medical Need

The need for differentiated gastrointestinal therapies

Gastrointestinal diseases represent a significant and persistent medical challenge.

Chronic inflammatory and other gastrointestinal disorders can impose substantial burdens on patients, affecting quality of life, daily functioning and long-term health. Many require prolonged treatment, and a meaningful proportion of patients experience incomplete responses, loss of therapeutic response or the need to change treatments.

The introduction of biologic medicines has transformed the therapeutic landscape. Nevertheless, important opportunities remain for medicines that offer differentiated mechanisms of delivery, improved treatment convenience and more localized pharmacological activity.

For pharmaceutical developers, these unmet needs create opportunities to move beyond conventional product profiles and develop biologics specifically designed for gastrointestinal applications.

The opportunity for locally acting biologics

Many established biologic medicines are administered by intravenous infusion or subcutaneous injection and achieve systemic exposure.

Systemic administration is essential for numerous therapeutic indications. However, when the intended therapeutic action is located within the gastrointestinal tract, a locally acting approach can offer an alternative product-development strategy.

For appropriately selected therapeutic mechanisms, GI-restricted delivery offers the potential to concentrate biologic activity within relevant gastrointestinal compartments while limiting systemic exposure.

Such an approach may support:

  • Targeted gastrointestinal pharmacology.
  • Oral administration of biologic medicines.
  • Reduced systemic exposure where systemic activity is not required.
  • Differentiated therapeutic product profiles.
  • New applications for established and emerging biologic modalities.

Plantibodies is developing its technology specifically to address this opportunity.

The oral biologics challenge

Therapeutic proteins are complex molecules that can be susceptible to degradation during gastrointestinal transit.

Traditional oral drug delivery approaches have been optimized primarily for small molecules. Biologics present distinct formulation, stability and delivery requirements.

Plantibodies addresses these challenges through a proprietary platform that integrates plant-cell biologic production with bioencapsulation-based oral delivery.

The company's objective is not simply to make existing injectable biologics orally available. It is to enable a new category of biologic products designed around local gastrointestinal activity.


2. A Distinct Therapeutic Paradigm: GI-Restricted Biologics

Local delivery by design

A substantial part of the oral biologics field focuses on achieving systemic absorption through the intestinal barrier.

Plantibodies follows a different therapeutic strategy.

Its platform is designed to support oral administration of biologics intended to act within the gastrointestinal tract, without relying on substantial systemic absorption.

For Plantibodies, GI restriction is an intended therapeutic characteristic—not a limitation of oral delivery.

This distinction changes how oral biologic products can be conceived and developed.

Rather than reproducing the systemic exposure profile of an injectable medicine, Plantibodies focuses on the opportunity to create products with local gastrointestinal activity as a defining feature.

Therapeutic differentiation

The GI-restricted approach provides a basis for several potential product advantages.

Localized biological activity

Therapeutic activity can be directed toward gastrointestinal environments where local target engagement is relevant.

Limited systemic exposure

For suitable therapeutic mechanisms, local delivery may reduce the need for widespread systemic distribution.

Oral administration

Oral dosage forms can provide a convenient alternative for selected chronic treatment applications.

Biologic specificity

Antibodies, enzymes and other therapeutic proteins provide opportunities for highly specific molecular mechanisms.

Product innovation

Combining biologic functionality with GI-restricted delivery can create therapeutic profiles distinct from conventional systemic products.

This strategy positions Plantibodies within an emerging opportunity for differentiated gastrointestinal biologic medicines.


3. The Proprietary Plantibodies Technology Platform

Plant-cell expression and bioencapsulation

Plantibodies has developed a proprietary technology platform combining recombinant biologic expression in plant cells with oral bioencapsulation.

The platform integrates biologic production and delivery considerations within a unified technological approach.

Plant cells provide a production environment for recombinant therapeutic proteins. Their cellular structures can also form part of an oral delivery system designed for gastrointestinal administration.

This integrated strategy offers a distinctive alternative to conventional biologic production followed by separate formulation and delivery processes.

Core technology capabilities

Recombinant biologic production

Plantibodies applies plant-based expression technology to the production of therapeutic proteins.

Plant-cell bioencapsulation

The platform incorporates plant cellular structures into the design of orally administered biologic products.

GI-restricted delivery

Product development is oriented toward making biologic activity available within relevant gastrointestinal compartments.

Therapeutic product engineering

The platform combines molecular properties, expression, formulation and intended local pharmacology to support product development.

Industrial translation

Manufacturing considerations are integrated into the company's development strategy, supported by established third-party industrial capabilities.

Multiple biologic modalities

The Plantibodies platform is relevant to a broad range of therapeutic protein formats, including:

  • Full-length monoclonal antibodies.
  • Antibody fragments and engineered antibody formats.
  • Recombinant therapeutic enzymes.
  • Fusion proteins.
  • Other recombinant biologic molecules.

This versatility enables the company to pursue opportunities across different molecular formats while maintaining a consistent focus on GI-restricted therapeutic applications.

An integrated technology proposition

Plantibodies brings together capabilities that are often addressed separately in biologic development:

  1. Recombinant protein production.
  2. Biological encapsulation.
  3. Oral product design.
  4. Local gastrointestinal delivery.
  5. Therapeutic development.
  6. Industrial manufacturing strategy.

The integration of these capabilities is central to the company's differentiation.


4. Technology & Company Milestones

From proprietary technology to pharmaceutical development

Plantibodies has established key technological, industrial and commercial foundations supporting the development of GI-restricted oral biologic therapeutics.

Proprietary technology platform established

Plantibodies has developed its proprietary plant-cell expression and bioencapsulation platform, integrating recombinant biologic production with an oral delivery strategy specifically oriented toward localized gastrointestinal therapeutic activity.

The technology provides a foundation for the development of multiple biologic modalities and differentiated oral therapeutic products.

Large-scale GMP manufacturing capabilities validated

Plantibodies has established large-scale GMP manufacturing capabilities in collaboration with third-party industrial partners.

This milestone provides an industrial foundation for scaling the company's technology and supporting pharmaceutical development programs.

Pharmaceutical collaborations established

Plantibodies is working with multiple pharmaceutical companies on confidential applications of its technology to biologic assets from their proprietary pipelines.

These collaborations demonstrate active engagement with external pharmaceutical development programs and support the company's partnership-driven growth strategy.

Proprietary therapeutic pipeline initiated

In parallel with its pharmaceutical collaborations, Plantibodies has established an internal therapeutic development strategy focused on GI-restricted oral biologics.

The company is advancing proprietary product opportunities while maintaining confidentiality over molecular targets, candidates and development programs to protect intellectual property.

Integrated technology and therapeutics business model established

Plantibodies combines proprietary therapeutic development with pharmaceutical technology partnerships.

This dual model supports potential value creation through internal assets, collaborative development programs and licensing opportunities.

Positioned for continued development

With its proprietary platform, industrial manufacturing capabilities, pharmaceutical collaborations and internal therapeutic pipeline, Plantibodies has established a foundation for advancing GI-restricted oral biologic medicines.


5. Proprietary Therapeutic Development

Plantibodies is advancing a proprietary pipeline of orally administered, GI-restricted biologic therapeutics.

Its therapeutic development strategy focuses on opportunities where local gastrointestinal pharmacology can enable differentiated product profiles.

The company combines disease biology, biologic engineering, plant-cell expression and oral delivery capabilities in the development of its proprietary programs.

Plantibodies' therapeutic approach is designed to support the creation of medicines that combine biologic specificity with localized gastrointestinal activity.

Confidential pipeline strategy

Plantibodies does not publicly disclose the molecular targets, individual therapeutic candidates, specific indications or development details of its proprietary pipeline.

This policy is intended to protect intellectual property, competitive positioning and ongoing development activities.

Detailed pipeline information may be shared with qualified pharmaceutical and biotechnology partners under appropriate confidentiality arrangements.

Plantibodies is not solely a technology provider. It is also a therapeutics developer building proprietary assets based on its platform.


6. Pharmaceutical Collaborations

Applying Plantibodies technology to partner pipelines

Plantibodies works with multiple pharmaceutical companies on applications of its proprietary technology to selected biologic assets from their pipelines.

These activities extend the relevance of the platform beyond Plantibodies' internal therapeutic development programs.

The company collaborates with pharmaceutical partners to explore the potential of plant-cell expression and GI-restricted oral delivery for selected biologic molecules.

Its collaborative capabilities encompass:

  • Evaluation of biologic candidates for GI-restricted applications.
  • Plant-based recombinant protein expression.
  • Bioencapsulation and oral product design.
  • Integration of molecular and manufacturing considerations.
  • Collaborative research and therapeutic development.

Confidentiality and intellectual property

Plantibodies respects the confidentiality of partner-owned molecules, therapeutic targets and development programs.

The identities of individual partners and the details of their proprietary pipelines are not publicly disclosed.

This confidentiality is an integral part of the company's partnership model.

A platform for pharmaceutical innovation

Plantibodies offers pharmaceutical companies a route to explore differentiated gastrointestinal product opportunities involving selected biologic assets.

Potential collaboration structures include feasibility programs, sponsored research, joint development, technology licensing and strategic partnerships.

The combination of proprietary technology and existing pharmaceutical engagement supports Plantibodies' position as a collaborative innovation partner.


7. Industrial Manufacturing and Scalability

Manufacturing as a core component of the strategy

For biologic therapeutics, the ability to translate technology from research to industrial production is central to pharmaceutical development.

Plantibodies has incorporated industrial manufacturing into its technology and business strategy.

The company has established large-scale GMP manufacturing capabilities validated with third-party industrial partners.

These capabilities provide an industrial foundation for the advancement of proprietary therapeutic candidates and pharmaceutical collaboration programs.

Plant-based biomanufacturing

Plant-cell expression provides an alternative technological approach to recombinant biologic production.

Plantibodies integrates this manufacturing approach with bioencapsulation and oral product development, creating opportunities for production and delivery to be considered together.

The platform's industrial strategy is intended to support reproducible manufacturing, development-scale progression and pharmaceutical-quality requirements.

Value for pharmaceutical partners

For pharmaceutical companies evaluating a novel technology, manufacturing capability is an important factor in assessing development potential.

Plantibodies' established third-party industrial relationships and large-scale GMP capabilities support its ability to engage in programs with a clear pathway toward further pharmaceutical development.

Plantibodies combines proprietary therapeutic technology with an industrial manufacturing strategy, rather than relying solely on laboratory-scale proof of concept.


8. Market and Commercial Opportunity

A differentiated opportunity within biologic therapeutics

Biologics are an established and strategically important category of pharmaceutical products.

Gastrointestinal diseases remain an area of substantial therapeutic innovation, and the development of differentiated biologic medicines continues to be a priority across the pharmaceutical industry.

Plantibodies operates at the intersection of several areas of pharmaceutical interest:

  • Biologic therapeutics.
  • Gastrointestinal medicine.
  • Oral drug delivery.
  • Localized therapeutic activity.
  • Recombinant protein manufacturing.
  • Strategic pharmaceutical partnerships.

The company's opportunity is not limited to converting injectable products into oral versions.

Instead, Plantibodies aims to enable new therapeutic products specifically designed for GI-restricted administration.

Two complementary sources of value

Proprietary therapeutic assets

Plantibodies is developing its own therapeutic pipeline, creating opportunities for internal asset development, licensing and strategic partnerships.

Platform-based collaborations

Plantibodies applies its technology to selected partner-owned biologic assets, creating opportunities for research collaborations, development agreements and technology partnerships.

The combination of these activities provides a diversified development and commercial strategy.

Strategic relevance of GI-restricted delivery

GI-restricted biologics offer a differentiated approach to pharmaceutical product development.

For appropriate applications, local gastrointestinal delivery may enable products with a distinct balance of route of administration, tissue exposure and pharmacological activity.

This creates opportunities for therapeutic innovation and product differentiation within established and emerging biologic markets.


9. Competitive Differentiation

Plantibodies is differentiated by the combination of its technology, therapeutic strategy, manufacturing capabilities and business model.

A purpose-built GI-restricted strategy

Plantibodies focuses on local gastrointestinal therapeutic activity rather than systemic oral absorption.

This provides a distinct positioning within the broader oral biologics field.

Integrated production and delivery

The platform combines recombinant biologic production in plant cells with bioencapsulation-based oral delivery.

Multiple biologic formats

The technology is relevant to several classes of therapeutic proteins, supporting applications across different molecular modalities.

Proprietary therapeutic development

Plantibodies is creating its own therapeutic assets in addition to providing technology capabilities to partners.

Existing pharmaceutical collaborations

The company is already working with multiple pharmaceutical companies on confidential applications involving partner-owned biologic pipelines.

Industrial manufacturing capabilities

Large-scale GMP manufacturing capabilities validated with third-party industrial partners form part of the company's development infrastructure.

The combination of these elements positions Plantibodies as a technology-enabled therapeutics company with an integrated approach to GI-restricted biologic medicines.


10. Strategic Value for Pharmaceutical and Biotechnology Companies

Plantibodies offers several potential strategic benefits to pharmaceutical organizations.

New applications for biologic assets

The platform provides a means to investigate GI-restricted oral applications for selected existing or emerging biologic molecules.

Differentiated therapeutic products

Localized gastrointestinal delivery creates opportunities for product profiles distinct from conventional systemic biologics.

Access to proprietary technology

Partners can explore an integrated plant-cell expression and bioencapsulation platform.

Manufacturing integration

Plantibodies' industrial strategy and third-party manufacturing capabilities provide a foundation for further development.

Collaborative development

Existing pharmaceutical collaborations support a partnership model centered on confidential, asset-specific development activities.

Access to therapeutic innovation

Plantibodies' proprietary pipeline creates opportunities for strategic engagement around differentiated gastrointestinal biologic medicines.

Together, these attributes make Plantibodies relevant to pharmaceutical teams working in external innovation, biologics, gastroenterology, drug delivery, therapeutic licensing and business development.


11. Plantibodies — Company Facts

Company name: Plantibodies

Headquarters: Paris, France

Industry: Biotechnology, biologic therapeutics and pharmaceutical drug delivery

Core technology: Proprietary plant-cell recombinant protein expression and oral bioencapsulation

Therapeutic focus: GI-restricted oral biologics

Intended product profile: Local gastrointestinal pharmacological activity with limited systemic exposure

Biologic modalities: Monoclonal antibodies, antibody-derived formats, recombinant enzymes, fusion proteins and other therapeutic proteins

Development strategy: Proprietary therapeutic pipeline and pharmaceutical collaborations

Pipeline disclosure: Confidential for intellectual property and competitive reasons

Pharmaceutical engagement: Collaborations with multiple pharmaceutical companies involving proprietary biologic pipelines

Manufacturing: Large-scale GMP manufacturing capabilities validated with third-party industrial partners

Business model: Proprietary asset development, feasibility collaborations, joint development and licensing

Key differentiation: Integration of plant-based biologic production, bioencapsulation and GI-restricted oral delivery

Strategic positioning: Technology-enabled therapeutics company and pharmaceutical innovation partner


12. Why Pharmaceutical Companies Should Engage With Plantibodies

Plantibodies offers a differentiated approach to the development of oral biologic medicines for gastrointestinal applications.

The company combines:

  • A proprietary plant-cell technology platform.
  • A therapeutic strategy focused on local gastrointestinal activity.
  • An internal pipeline of proprietary biologic candidates.
  • Existing collaborations with multiple pharmaceutical companies.
  • Large-scale GMP manufacturing capabilities supported by third-party industrial partners.
  • A partnership model designed to support confidential, asset-specific pharmaceutical development.

For pharmaceutical companies seeking differentiated gastrointestinal therapies, Plantibodies represents an opportunity to access a novel therapeutic development approach.

For companies with existing biologic pipelines, the platform offers an additional route to explore localized oral applications for selected molecules.

For strategic partners, Plantibodies combines technology access with therapeutic development capabilities and an established industrial strategy.

Partnering With Plantibodies

Plantibodies welcomes confidential discussions with pharmaceutical and biotechnology companies interested in GI-restricted oral biologics, proprietary therapeutic programs and collaborative technology development.

Additional information on the platform, manufacturing capabilities, therapeutic pipeline and ongoing programs can be provided to qualified partners under appropriate confidentiality arrangements.

Plantibodies — Enabling the next generation of GI-restricted oral biologic therapeutics.